COMPANY

Epigen Biosciences

HQ: San Diego, CA source · epigenbiosciences.com ↗ · West Coast

Also known as EPIGEN BIOSCIENCES INC · 41 sources

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

40NIH grants

Timeline

Sep 11, 2025 Grant Government grant — STTR: $349,999 (annual award, as published), announced Sep 11, 2025. Agency: NIH/NIGMS. Source: government award database. source ↗

Funding

Last 2 years.

Sep 11, 2025 Government grant — STTR: $349,999 (annual award, as published), announced Sep 11, 2025. Agency: NIH/NIGMS. Source: government award database. source ↗

NIH awards 40

Annual award amounts. Total $20.8M.

Jul 11, 2024 NIH award 5R44DK129071-03 FY2024: $1,041,548 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Candidate selection of a LPAR1 ant source ↗
May 28, 2024 NIH award 1R43NS135837-01A1 FY2024: $550,864 awarded for that fiscal year; activity R43 (SBIR); PI UTESHEV, VICTOR V; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel Product Formulation toModulat source ↗
Aug 23, 2023 NIH award 2R44DK129071-02 FY2023: $971,732 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Candidate selection of a LPAR1 antag source ↗
May 31, 2023 NIH award 1R43DK134242-01A1 FY2023: $448,110 awarded for that fiscal year; activity R43 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. New Therapy for the Treatment of P source ↗
May 6, 2022 NIH award 5R44DK127879-02 FY2022: $990,691 awarded for that fiscal year; activity R44 (SBIR); PI BEATON, GRAHAM; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Selection of a lead LPAR1 antagonist for source ↗
Apr 20, 2022 NIH award 5R44MH115529-04 FY2022: $1,157,216 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel therapy for Fragile X syndro source ↗
Sep 20, 2021 NIH award 1R43DK129071-01A1 FY2021: $397,398 awarded for that fiscal year; activity R43 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Lead candidate identification of L source ↗
Aug 20, 2021 NIH award 3R44MH115529-03S1 FY2021: $50,000 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Administrative supplement for Novel source ↗
May 20, 2021 NIH award 1R44DK127879-01A1 FY2021: $1,035,811 awarded for that fiscal year; activity R44 (SBIR); PI BEATON, GRAHAM; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Selection of a lead LPAR1 antagonist source ↗
May 19, 2021 NIH award 1R43AG071335-01A1 FY2021: $449,984 awarded for that fiscal year; activity R43 (SBIR); PI RAVULA, SATHEESH B; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Evaluation of Alzheimers disease e source ↗
Apr 12, 2021 NIH award 2R44MH115529-03 FY2021: $998,958 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel therapy for Fragile X syndrome source ↗
Dec 3, 2020 NIH award 1U18DA052553-01 FY2021: $192,907 awarded for that fiscal year; activity U18 (OTHER_NIH); PI BEATON, GRAHAM; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel modulators of ÃÂÃÂ±7 nAChR source ↗
Jul 30, 2020 NIH award 1R43DK123920-01A1 FY2020: $375,033 awarded for that fiscal year; activity R43 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Assessment of a selective kinase i source ↗
Jun 2, 2020 NIH award 5R44DK092005-06 FY2020: $999,838 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Development of a novel therapeutic f source ↗
Apr 30, 2020 NIH award 1R43HL150986-01A1 FY2020: $299,983 awarded for that fiscal year; activity R43 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel agents for idiopathic pulmon source ↗
Mar 23, 2020 NIH award 5R44AG043243-04 FY2020: $1,322,759 awarded for that fiscal year; activity R44 (SBIR); PI RAVULA, SATHEESH B; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Lead optimization and development source ↗
Sep 19, 2019 NIH award 1R43DE029379-01 FY2019: $390,335 awarded for that fiscal year; activity R43 (SBIR); PI FRIEDMAN, CRAIG; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Therapeutic in Situ Analgesic Implant f source ↗
Aug 9, 2019 NIH award 2R44AG043243-03 FY2019: $1,169,102 awarded for that fiscal year; activity R44 (SBIR); PI RAVULA, SATHEESH B; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Lead optimization and development source ↗
Jul 25, 2019 NIH award 5R44DK092005-05 FY2019: $999,274 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Development of a novel therapeutic f source ↗
Sep 5, 2018 NIH award 1R43DK117758-01A1 FY2018: $298,946 awarded for that fiscal year; activity R43 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Assessment of LPA1R antagonists in source ↗
Aug 23, 2018 NIH award 1R43AR072546-01A1 FY2018: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI RAVULA, SATHEESH B; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. New Approach to Atopic Dermatitis source ↗
Jun 20, 2018 NIH award 5R41MH115529-02 FY2018: $317,514 awarded for that fiscal year; activity R41 (STTR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel therapy for Fragile X syndrome source ↗
Jun 18, 2018 NIH award 2R44DK092005-04 FY2018: $999,500 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Development of a novel therapeutic f source ↗
Sep 26, 2017 NIH award 3R41MH115529-01S1 FY2017: $117,346 awarded for that fiscal year; activity R41 (STTR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel therapy for Fragile X syndro source ↗
Sep 19, 2017 NIH award 1R41NS098903-01A1 FY2017: $417,267 awarded for that fiscal year; activity R41 (STTR); PI UTESHEV, VICTOR V; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel Treatment for Traumatic Brain source ↗
Sep 14, 2017 NIH award 1R41MH115529-01 FY2017: $399,938 awarded for that fiscal year; activity R41 (STTR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel therapy for Fragile X syndrome source ↗
Sep 1, 2016 NIH award 3R44DK092005-03S1 FY2016: $2,000 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Development of novel agents for the source ↗
Sep 14, 2015 NIH award 1R43DK105654-01A1 FY2015: $228,661 awarded for that fiscal year; activity R43 (SBIR); PI JENKINSON, CELIA; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Novel integrin inhibitors for kidney source ↗
Aug 26, 2015 NIH award 5R44DK092005-03 FY2015: $835,306 awarded for that fiscal year; activity R44 (SBIR); PI TUCCI, FABIO COHEN; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. Development of novel agents for the source ↗
Sep 9, 2014 NIH award 3R41NS086244-01A1S1 FY2014: $25,000 awarded for that fiscal year; activity R41 (STTR); PI RAVULA, SATHEESH B; recipient as written: EPIGEN BIOSCIENCES, INC., SAN DIEGO, CA. I-Corps training for 1R41NS086244 source ↗